Final results from M72 AS01E TB Vaccine Trial
The final results from the M72AS01E TB vaccine study have been published in the New England Journal of Medicine. The vaccine demonstrated a 50% efficacy rate in the incidence of lung TB disease in HIV-negative adults, already infected with latent...
Community Engagement
Carina's Choice: SATVI collaborated with UCT Drama Department and Worcester Secondary School in developing this play which was performed by learners from Worcester Secondary School at 8 local high schools reaching approximately 8 000 adolescents in...
Phase 3 efficacy study finds shortened 4-month TB drug therapy treatment equivalent to 6-months therapy
The New England Journal of Medicine has published the results of a clinical study which shows that in a randomised phase 3 clinical trial, a shortened 4-month TB treatment was equivalent to the standard 6-month TB treatment.
2020 Annual Report
The SATVI 2020 Annual Report is available for download.
New multi-functional TB blood test validated
Researchers the South African Tuberculosis Vaccine Initiative (SATVI), the Center for Global Infectious Disease Research(USA) and a large consortium of collaborators have developed a validated a new, simple blood-based test that has the potential to...


Friday, 24 September 2021
26 March 2021 In-depth: SA at cutting edge of TB vaccine research

Today, on the 26 March 2001 the 1st participant in the first SATVI BCG- randomised clinical trial was enrolled. Adele Baleta writes in the Daily Maverick about the work that the South African Tuberculosis Vaccine Initiative has been doing the past 20 years in fighting TB. 

Publication Date:
Fri, 26 Mar 2021 - 19:30
26 March 2021 Celebrating 20 years of TB research

On Friday 26 March 2021, SATVI will celebrate its 20th birthday to mark the enrolment in 2001 of the first participant in the first SATVI TB vaccine trial a randomised controlled trial of intradermal vs percutaneous BCG vaccination, Hawkridge BMJ 2008.

Publication Date:
Thu, 25 Mar 2021 - 22:45
21 March 2021 TB vaccine moves into phase II study in people living with HIV.

Cape Town:  Researchers at the South African Tuberculosis Vaccine Initiative (SATVI) research site in Worcester have started recruitment for a phase II vaccine trial to see  if the M72/AS01E TB vaccine is safe and immunogenic in people living with HIV. 

Publication Date:
Tue, 23 Mar 2021 - 16:00
4 February 2021 Opinion piece: How we know vaccines are safe and effective

Associate Professor Elisa Nemes, Dr Michele Tameris, Dr Virginie Rozot, Professor Thomas Scriba, and Dr Benjamin Kagina have written an opinion piece in which they explain the process vaccines and drugs have to go through before they can be approved for human use. This article appeared in the Health 24.

Publication Date:
Fri, 05 Feb 2021 - 21:30